See the DrugPatentWatch profile for rybrevant
How common are infusion reactions with Rybrevant (amivantamab)?
Infusion reactions are a known risk with Rybrevant (amivantamab). In the prescribing information, infusion-related events are monitored closely and patients are given premedication to reduce the chance and severity of reactions. The label also describes dose interruptions and discontinuation criteria if an infusion reaction occurs.
What kinds of symptoms count as an infusion reaction?
Infusion reactions can range from mild to severe and can include reactions that occur during or shortly after the infusion. The risk management approach in the label (premedication plus monitoring during infusions) is designed to catch these reactions early and manage them promptly.
How is the risk reduced before and during infusions?
Rybrevant administration includes precautions such as premedication and close observation during infusions. If symptoms occur, the infusion can be slowed or paused, and treatment may be resumed or stopped depending on the severity of the reaction, consistent with the prescribing information’s management guidance.
What happens if a patient has an infusion reaction?
Management depends on severity. The label provides instructions for holding the dose, adjusting the infusion, or discontinuing Rybrevant if a reaction is severe or recurrent. This is why patients are typically observed during infusion and are instructed to report symptoms immediately.
What patient factors increase risk?
The prescribing information focuses on reaction prevention and severity-based management rather than one single risk factor. Practically, patients with a history of infusion reactions to similar biologic therapies, or who experience symptoms during early infusions, may be managed more cautiously with stricter monitoring and treatment modifications.
Are infusion reactions different from other side effects?
Yes. Infusion reactions are events tied to the act of infusing the drug (during or shortly after infusion). Other risks with Rybrevant, such as skin reactions and other drug-related adverse effects, are separate from infusion reactions and follow different grading and management pathways.
Source